Exports of Biosimilar Drugs to Get Boost (India)
This article was originally published in PharmAsia News
The Indian Pharmaceutical Export Promotion Council (Pharmexcil) is developing a specific biotech export-program to promote biosimilar drugs because there is increasing demand for biosimilar drugs in the United States and Europe. Pharmexcil is looking to work with Indian industry groups on this. Experts believe that the biosimilar market by 2015 will total $30 billion in U.S. sales and $25 billion in European sales. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.